Reporting on the real-world utilization of reference rituximab and its biosimilars can help show prescribing habits and reveal cost-saving opportunities. Objectives: Limited data exist on the adoption ...

Research on characteristics of the biopharmaceutical pipeline and on changes since 2003 includes a description of new features and recommendations for health policy decision makers. : To quantify and ...

Investing.com - Canaccord Genuity raised its price target on Palvella Therapeutics (NASDAQ:PVLA) stock to $90.00 from $66.00 on Thursday, while maintaining a Buy rating following the company’s ...

Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced the selection of a subgroup of atopic dermatitis (AD) patients, not responding to first line dupilumab treatment, as its second ...

“The estimated size of these U.S. markets versus our projected clinical trial costs clearly warrant pursuing FDA approvals in these indications. The ability to use the SCD as currently configured, ...

Investing.com - H.C. Wainwright raised its price target on Palvella Therapeutics (NASDAQ:PVLA) to $95.00 from $75.00 on Friday, while maintaining a Buy rating on the stock. The new target represents ...